University of Birmingham has spun out Viatem to develop a treatment for rheumatoid arthritis.

The Cambridge spinout has raised $15m in series A funding from investors including Cambridge Enterprise and Parkwalk Advisors.

Baylor College of Medicine immuno-oncology spinout Marker Therapeutics is to merge with publicly-listed TapImmune, which has set up a $70m private placement to support the new entity.

Global University Venturing's data review and roundup of funds investing in spinouts.

NUS spinout MediSix has obtained $20m from investors including Osage University Partners to commercialise research into leukaemia and lymphoma treatments.

Andrew Gaule discusses tech transfer and university incubation with Tal Badt, X-lab Tsinghua University, and Quentin Compton-Bishop, Warwick Ventures.

Beam has emerged out of Harvard University with $87m in series A funding to commercialise gene editing technology, with additional research licensed from Broad Institute and Editas Medicine.